http://bmj.com/cgi/content/full/324/7335/444/d
BMJ 2002;324:444 ( 23 February )
Fred Charatan Florida
Last month, faculty members at the Harvard School of Public Health decided that
it would "not accept any grant or anything else of value from any tobacco
manufacturer, distributor, or other tobacco related company."
The vote not to accept research funding from tobacco manufacturers and their
subsidiaries, puts current practice into official policy and is consistent with
Harvard University’s 13 year old policy of not holding stock in tobacco
companies.
"I believe the decision by the faculty represents a powerful statement
from public health professionals that we must all focus on efforts to prevent
the addiction and terrible consequences of tobacco," said Barry Bloom,
dean of the Harvard School.
The decision meets general policy that was recently agreed to by the deans
of the 31 member Association of Schools of Public Health so that it could
distribute research funds from the American Legacy Foundation. This public
health foundation was established by the tobacco industry’s 1998 settlement of
lawsuits brought by a coalition of attorneys general in 46 states and five US
territories.
The Harvard School of Public Health comprises more than 300 faculty members
engaged in teaching and training more than 800 students in a broad spectrum of
disciplines crucial to the health and wellbeing of individuals and populations
around the world.
Programmes and projects range from the molecular biology of
AIDS vaccines to the epidemiology of cancer; from risk analysis to violence
prevention; from maternal and child health to quality of care management; and
from healthcare management to international health and human rights.
ALL INFORMATION, DATA,
AND MATERIAL CONTAINED, PRESENTED, OR PROVIDED HERE IS FOR GENERAL INFORMATION
PURPOSES ONLY AND IS NOT TO BE CONSTRUED AS REFLECTING THE KNOWLEDGE OR
OPINIONS OF THE PUBLISHER, AND IS NOT TO BE CONSTRUED OR INTENDED AS PROVIDING
MEDICAL OR LEGAL ADVICE. THE DECISION WHETHER OR NOT TO VACCINATE IS AN
IMPORTANT AND COMPLEX ISSUE AND SHOULD BE MADE BY YOU, AND YOU ALONE, IN
CONSULTATION WITH YOUR HEALTH CARE PROVIDER.
|